ישראל - עברית - Ministry of Health

sanofi israel ltd - belumosudil as mesylate - טבליות מצופות פילם - belumosudil as mesylate 200 mg - belumosudil

ישראל - עברית - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - טבליות מצופות פילם - sevelamer carbonate anhydrous 800 mg - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

ישראל - עברית - Ministry of Health

sanofi israel ltd - sevelamer carbonate anhydrous - אבקה להכנת תרחיף - sevelamer carbonate anhydrous 2.4 g/sachet - sevelamer - sevelamer - for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.also indicated for the control of hyperphosphataemia in adult patients with chronic kidney diseasenot on dialysis with serum phosphorus ? 1.78 mmol/l.should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - aluminium hydroxide; magnesium hydroxide - תרחיף - aluminium hydroxide 175 mg / 5 ml; magnesium hydroxide 200 mg / 5 ml - ordinary salt combinations - ordinary salt combinations - antacid.

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - imiglucerase 200 u/vial - powder for solution for infusion - imiglucerase - for the long term enzyme replacement therapy for patients with a confirmed diagnosis of type 1 gaucher disease that results in one or more of the following conditions: - anemia , - thrombocytopenia , - bone disease , - hepatomegaly or splenomegaly.

ישראל - עברית - Ministry of Health

sanofi israel ltd - imiglucerase - אבקה להכנת תמיסה מרוכזת לעירוי - imiglucerase 400 u/vial - imiglucerase - imiglucerase - for the long term enzyme replacement therapy for patients with a confirmed diagnosis of type 1 gaucher disease that results in one or more of the following conditions: - anemia - thrombocytopenia - bone disease - hepatomegaly or splenomegaly.

ישראל - עברית - Ministry of Health

sanofi israel ltd - agalsidase beta - אבקה להכנת תמיסה מרוכזת לעירוי - agalsidase beta 35 mg/vial - agalsidase beta - agalsidase beta - fabrazyme is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease. (alfa - galactosidase a deficiency).

ישראל - עברית - Ministry of Health

sanofi - aventis israel ltd - agalsidase beta 5 mg/ml - powder for concentrate for infusion - agalsidase beta - long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease.

ישראל - עברית - Ministry of Health

sanofi israel ltd - laronidase - תרכיז להכנת תמיסה לאינפוזיה - laronidase 500 units / 5 ml - laronidase - laronidase - aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis i (mps i alfa-l-iduronidase deficiency) to treat the non-neurological manifestations of the disease.

ישראל - עברית - Ministry of Health

sanofi israel ltd - alglucosidase alfa - אבקה להכנת תרכיז לאינפוזיה - alglucosidase alfa 50 mg/vial - alglucosidase alfa - alglucosidase alfa - myozyme is indicated for long-term enzyme replacement therapy (ert) in patients with a confirmed diagnosis of pompe disease (acid alpha-glucosidase deficiency). the benefits of myozyme in patients with late-onset pompe disease have not been established.